SEC charges for­mer Medi­va­tion ex­ec with in­sid­er trad­ing pri­or to Pfiz­er ac­qui­si­tion

With­in min­utes of re­ceiv­ing high­ly con­fi­den­tial news that Medi­va­tion would be ac­quired by Pfiz­er for $14 bil­lion, Medi­va­tion ex­ec Matthew Panuwat rushed back to his …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER